<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01599884</url>
  </required_header>
  <id_info>
    <org_study_id>MVMREF-001</org_study_id>
    <nct_id>NCT01599884</nct_id>
    <nct_alias>NCT01639963</nct_alias>
  </id_info>
  <brief_title>N-Acetylcysteine for Patients With COPD and ChronicBronchitis</brief_title>
  <official_title>Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Veterans Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center for Veterans Research and Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is&#xD;
      widely prescribed for patients with chronic obstructive pulmonary disease (COPD),&#xD;
      particularly for those who have accompanying symptoms of chronic cough and sputum production.&#xD;
      Randomized, placebo controlled indicate that it is safe and that it may have some clinical&#xD;
      benefit when used at relatively low doses. It is postulated that substantially higher doses&#xD;
      of NAC will be well-tolerated and will provide better symptom control while also decreasing&#xD;
      blood makers of oxidant stress and inflammation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the St. George's Respiratory Questionnaire</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-acetylcysteine, 1800 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical to active drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>1800 mg twice daily for 8 weeks</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral acetylcysteine</intervention_name>
    <description>Identical placebo pills twice daily for 8 weeks</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria&#xD;
&#xD;
               -  Capability to provide written informed consent&#xD;
&#xD;
               -  Age ≥ 40 years and ≤ 85 years&#xD;
&#xD;
               -  FEV1/FVC ratio (post bronchodilator) &lt; 70%&#xD;
&#xD;
               -  FEV1 (post bronchodilator) &lt; 65%&#xD;
&#xD;
               -  Presence of chronic cough and sputum production defined as the following:&#xD;
&#xD;
          -  Presence of chronic cough and sputum will be defined by responses to the first two&#xD;
             questions on the SGRQ (see Appendix A). Subjects who respond positively to both&#xD;
             question 1 (cough) and question 2 (sputum) on the SGRQ as either &quot;several days per&#xD;
             week&quot; or &quot;almost every day&quot; will be eligible&#xD;
&#xD;
               -  Current or former smoker with lifetime cigarette consumption of at least 10&#xD;
                  pack-years&#xD;
&#xD;
               -  Negative serum pregnancy test at the baseline visit if patient is a&#xD;
                  pre-menopausal female (menopause defined as absence of a menstrual cycle in the&#xD;
                  last 12 months)&#xD;
&#xD;
               -  Must be fluent in speaking the English language&#xD;
&#xD;
          -  Exclusion Criteria&#xD;
&#xD;
               -  Not fully recovered for at least 30 days from a COPD exacerbation characterized&#xD;
                  by typical symptoms and treated with antibiotics or prednisone&#xD;
&#xD;
               -  Known allergy or sensitivity to NAC or albuterol&#xD;
&#xD;
               -  Any patient with unstable cardiac disease&#xD;
&#xD;
               -  Any patient with a documented history of uncompensated congestive heart failure&#xD;
                  in the last 2 years&#xD;
&#xD;
               -  Clinical diagnosis of asthma, bronchiectasis, cystic fibrosis, or severe alpha-1&#xD;
                  antitrypsin deficiency&#xD;
&#xD;
               -  Active lung cancer or history of lung cancer if it has been less than 2 years&#xD;
                  since lung resection or other treatment. If history of lung cancer, must have no&#xD;
                  evidence of recurrence in the 2 years preceding the baseline visit.&#xD;
&#xD;
               -  Undergoing active treatment for malignancy except for hormonal therapy (i.e.&#xD;
                  prostate cancer, breast cancer) or non-metastatic skin cancer and are not&#xD;
                  symptomatic&#xD;
&#xD;
               -  Chronic kidney disease with an estimated GFR of &lt; 30 ml/min. GFR will be&#xD;
                  estimated using the Modification of Diet in Renal Disease (MDRD) formula&#xD;
&#xD;
               -  History of cirrhosis with evidence of portal hypertension (ascites, chronic&#xD;
                  edema)&#xD;
&#xD;
               -  Participation in a pulmonary rehabilitation program or completion within past 6&#xD;
                  weeks&#xD;
&#xD;
               -  Prisoners or institutionalized patients&#xD;
&#xD;
               -  Participation in another study involving an investigational product within 30&#xD;
                  days of the baseline visit&#xD;
&#xD;
               -  Pregnant or breast-feeding patients.&#xD;
&#xD;
               -  Use of guaifenesin in the last 30 days&#xD;
&#xD;
               -  Currently on long acting nitrates for angina or heart failure&#xD;
&#xD;
               -  Abnormalities in screening blood work defined as:&#xD;
&#xD;
          -  WBC &lt; 3.0 or &gt; 15.0 K/cmm&#xD;
&#xD;
          -  Hemoglobin &lt; 9.0 or &gt; 17.0 gm/dl&#xD;
&#xD;
          -  Platelets &lt; 75 or &gt; 400 K/cmm&#xD;
&#xD;
          -  ALT &gt; 3 times the upper limit of normal&#xD;
&#xD;
          -  INR &gt; 1.5 unless on warfarin therapy o Any concomitant condition that might endanger&#xD;
             the patient through participation in the study or interfere with study procedures, as&#xD;
             assessed by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Niewoehner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Veterans Affairs Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dennis Niewoehner</last_name>
    <phone>612-467-4412</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Dennis Niewoehner, MD</last_name>
      <phone>612-467-4412</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2012</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center for Veterans Research and Education</investigator_affiliation>
    <investigator_full_name>Dennis Niewoehner</investigator_full_name>
    <investigator_title>Staff physician</investigator_title>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <keyword>Chronic bronchitis</keyword>
  <keyword>N-acetylcysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 30, 2015</submitted>
    <returned>November 2, 2015</returned>
    <submitted>March 21, 2018</submitted>
    <returned>April 19, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

